

AR-1 Human Subjects Requirements  
 AR-2 Requirement for Inclusion of Women  
 and Racial and Ethnic Minorities in  
 Research  
 AR-7 Executive Order 12372 Review  
 AR-9 Paperwork Reduction Act  
 Requirements  
 AR-10 Smoke-Free Workplace Requirements  
 AR-11 Healthy People 2010  
 AR-12 Lobbying Restrictions

### J. Where To Obtain Additional Information

This and other CDC announcements, the necessary applications, and associated forms can be found on the CDC web site, Internet address: <http://www.cdc.gov>. Click on "Funding" then "Grants and Cooperative Agreements."

For general questions about this announcement, contact: Technical Information Management, CDC Procurement and Grants Office, 2920 Brandywine Road, Room 3000, Atlanta, GA 30341-4146. Telephone (770) 488-2700.

For business management and budget assistance in the States, contact: Angela Webb, Grants Management Specialist, Acquisition and Assistance Branch B, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 2920 Brandywine Road, Room 3000, Atlanta, GA 30341-4146. Telephone (770) 488-2784. Email address: [AQW6@cdc.gov](mailto:AQW6@cdc.gov).

For business management and budget assistance in the Territories, contact: Terri Brown, Grants Management Specialist, International & Territories Acquisition and Assistance Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 2920 Brandywine Road, Room 3000, Atlanta, Georgia 30341-4146. Telephone (770) 488-2638. Email address: [aie9@cdc.gov](mailto:aie9@cdc.gov).

For program technical assistance, contact: Patricia L. Mitchell, MPH, Health Comm. Section Chief, Program Development Branch, DDT, NCCDPHP, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, MS K10, Atlanta, GA 30341-3717. Telephone (770) 488-5634. Email address: [plm3@cdc.gov](mailto:plm3@cdc.gov).

Dated: November 12, 2002.

#### Edward Schultz,

*Acting Director, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 02-29837 Filed 11-22-02; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 99N-5556]

#### Agency Information Collection Activities; Announcement of OMB Approval; Food Contact Substances Notification System

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Food Contact Substances Notification System" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

**FOR FURTHER INFORMATION CONTACT:** Peggy Robbins, Office of Information Resources Management (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1223.

**SUPPLEMENTARY INFORMATION:** In the *Federal Register* of May 21, 2002 (67 FR 35724), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0495. The approval expires on November 30, 2005. A copy of the supporting statement for this information collection is available on the Internet at <http://www.fda.gov/ohrms/dockets>.

Dated: November 14, 2002.

**Margaret M. Dotzel,**

*Associate Commissioner for Policy.*

[FR Doc. 02-29807 Filed 11-22-02; 8:45 am]

BILLING CODE 4160-01-S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration

(FDA). The meeting will be open to the public.

*Name of Committee:* Endocrinologic and Metabolic Drugs Advisory Committee.

*General Function of the Committee:* To provide advice and recommendations to the agency on FDA's regulatory issues.

*Date and Time:* The meeting will be held on January 13, 14, and 15, 2003, from 8 a.m. to 5 p.m.

*Location:* Holiday Inn, Versailles Ballrooms, 8120 Wisconsin Ave., Bethesda, MD.

*Contact Person:* Karen M. Templeton-Somers, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, (for express delivery, 5630 Fishers Lane, rm. 1093) Rockville, MD 20857, 301-827-7001, FAX 301-827-6776, e-mail: [somersk@cder.fda.gov](mailto:somersk@cder.fda.gov), or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12536. Please call the Information Line for up-to-date information on this meeting.

*Agenda:* On January 13, 2003, the committee will discuss the safety and efficacy of biologic licensing application BL 103979, FABRAZYME (agalsidase beta, Genzyme Corp.) for the treatment of Fabry's disease. On January 14, 2003, the committee will discuss the safety and efficacy of biologic licensing application BL 103977, REPLAGAL (agalsidase alfa, Transkaryotic Therapies, Inc.) for the treatment of Fabry's disease. On January 15, 2003, the committee will discuss the safety and efficacy of biologic licensing application BL 125058, ALDURAZYME (laronidase, BioMarin Pharmaceutical, Inc.) for the treatment of mucopolysaccharidosis.

*Procedure:* Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by January 6, 2003. Oral presentations from the public will be scheduled between approximately 11 a.m. and 12 noon. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before January 6, 2003, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Karen M. Templeton-Somers at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: November 15, 2002.

**Linda Arey Skladany,**

*Senior Associate Commissioner for External Relations.*

[FR Doc. 02-29808 Filed 11-22-02; 8:45 am]

BILLING CODE 4160-01-S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Indian Health Service

#### Indian Women's Health Demonstration Program for American Indians and Alaska Natives

**AGENCY:** Indian Health Service, HHS.

**ACTION:** Extension of deadlines for competitive applications for the Indian Women's Health Demonstration Program for American Indians and Alaska Natives.

The Notice of funding availability for competitive grants for Indian Women's Health Demonstration Program for American Indians and Alaska Natives was published at 67 FR 66410 on October 31, 2002.

The Indian Health Service announces the extension of dates for the following:

1. *Application Receipt Date:* January 3, 2003.
2. *Application Review:* January 23-24, 2003.
3. *Applicants Notified of Results (approved, approved unfunded, or disapproved):* February 13, 2003.
4. *Anticipated Start of Grant Cycle:* March 1, 2003.

Applicants are notified in writing on or about February 13, 2003.

This extension provides applicants approximately four additional weeks to prepare and submit competitive applications.

All other information contained in **Federal Register** announcement remains unchanged.

Dated: November 18, 2002.

**Charles W. Grimm,**

*Assistant Surgeon General, Interim Director, Indian Health Service.*

[FR Doc. 02-29865 Filed 11-22-02; 8:45 am]

BILLING CODE 4160-16-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Office of Director, National Institutes of Health; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Advisory Committee to the Director, National Institutes of Health (NIH).

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in section 552b(c)(9)(B), Title 5 U.S.C., as amended because the premature disclosure of information and the discussions would likely to significantly frustrate implementation of recommendations.

*Name of Committee:* Advisory Committee to the Director, NIH.

*Date:* December 5, 2002.

*Open:* 8 a.m. to 12 p.m.

*Agenda:* Among the topics proposed for discussion are: (1) Current issues (2) advice on priority areas for the NIH Director and (3) a summary of future action items and follow up items.

*Place:* National Institutes of Health, 9000 Rockville Pike, Conference Room 6, Building 31C, Bethesda, MD 20892.

*Closed:* 1 p.m. to 5 p.m.

*Agenda:* Review and evaluate confidential budgetary items.

*Place:* National Institutes of Health, 9000 Rockville Pike, Conference Room 6, Building 31C, Bethesda, MD 20892.

*Contact Person:* Ruth L. Kirschstein, M.D., Deputy Director, NIH, National Institutes of Health, 1 Center Drive MSC 0148, Building 1, Room 126, Bethesda, MD 20892-0148, 301-496-2433, [rk25n@nih.gov](mailto:rk25n@nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance into the building by non-government employees. Persons without a government I.D. will need to show a photo I.D. and sign-in at the security desk upon entering the building.

Information is also available on the home page: <http://www.nih.gov/about/director/acd.htm>, where an agenda and any additional information for the meeting will be posted when available.

Dated: November 15, 2002.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 02-29840 Filed 11-22-02; 8:45 am]

BILLING CODE 4140-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Cancer Advisory Board, December 4, 2002, 8:45 a.m. to December 5, 2002, 12 p.m., which was published in the **Federal Register** on November 8, 2002, 67 FR 68148.

The meeting time has been changed to start at 8:30 a.m. on Wednesday, December 4, 2002. The Subcommittee on Planning and Budget meeting which was scheduled on Wednesday, December 4, 2002 has been cancelled. The meeting is partially closed to the public.

Dated: November 15, 2002.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 02-29842 Filed 11-22-02; 8:45 am]

BILLING CODE 4140-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel. Cooperative Clinical Trial for Pediatric Transplantation.